

# Meeting Notice

## North Dakota Medicaid Drug Use Review Board

Wednesday, June 5<sup>th</sup>, 2024

1 to 4 p.m. Central Time

### In-Person Information

Conference Room 210/212, 2<sup>nd</sup> Floor, Judicial Wing, State Capitol  
600 E. Boulevard Ave., Bismarck

### Virtual Information

Join virtually: [Click here to join the meeting](#)

Join by phone: 701-328-0950, Conference ID: 876 672 920 #

### Agenda

1. Call to Order
2. Roll Call
3. Review and Approval of Minutes
4. Reports from Department
  - Administrative Report: Utilization Review
  - Financial Report: Top Drugs
  - Retrospective DUR Report
  - Clinical Report:
    - Prior Authorization Update
    - Criteria updates: Food Allergy (Xolair), Peanut Allergy (Palfozia), Reduce Risk of Major Adverse Cardiovascular Events (Wegovy), Pulmonary Hypertension (Wenrevair), Tardive Dyskinesia (Ingrezza, Austedo)
5. Special Orders: Presiding Officer and Vice-Presiding Officer Elections
6. Unfinished Business: Update to Hyperkalemia
7. New business
  - Second Review of Acid Blockers (Voquezna)
  - Second Review of Seborrheic Dermatitis (Zoryve)
  - Second Review of Primary Hyperoxaluria Type 1 (Rivfloza)
  - Second Review of Myasthenia Gravis (Zilbrysq)
  - Second Review of Duchenne Muscular Dystrophy (Emflaza, Agamree)
  - Second Review of Paroxysmal Nocturnal Hemoglobinuria (Empaveli, Fabhalta)
  - First Review of Molluscum Cantagiosum (Ycanth and Zelsuvmi)
  - First Review of Epidermolysis Bullosa (Filsuvez)
  - First Review of Metabolic Dysfunction–Associated Steatohepatitis (Rezdiffra)
  - Review of retrospective DUR criteria recommendations
8. Announcements: Next Meeting (September 4, 2024)
9. Adjourn

*Individuals with disabilities who need accommodations, including appropriate auxiliary aids to participate, can contact Ashley Gerving at 701-328-2354, toll-free 800-755-2604, 711 (TTY) or [gervingashley@nd.gov](mailto:gervingashley@nd.gov).*